BPs exhibit specific affinity towards bone, which makes them an excellent therapeutic for bone resorption diseases (especially osteoporosis, Paget's disease, tumour induced osteolysis, hypercalcemia originated from malignancy) by inhibition of farnesyl diphosphate synthase (FPPS) and for bone tumour caused by metastatic breast tumours [3–5]. This evidence concerns the gene FDPS and hypercalcemia disease.